Shares of Anthem Biosciences rallied 31 per cent over the IPO price of ₹570 on the listing day.
The stock debuted at a 26.85 per cent premium on bourses, and soared to a high of ₹746.70 against listing price of ₹723.10 on the BSE, and reaching a high of ₹747 after listing at ₹723.05 on the NSE.
Market experts cheered as one of the leading global players in the innovation-driven, technology-focused CRDMO segment.
Commenting on the market debut, Anthem Biosciences from Shivani Nyati, Head of Wealth at Swastika Investmart Ltd., said. “It enjoys a niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods.”
Nyati recommended investors to secure partial profits and retain the remainder with a stop-loss set at ₹650.
The ₹3,395 crore IPO was subscribed 63.86 times on the closing day of bidding, driven by overwhelming participation from institutional buyers. The price band was fixed at ₹540-570 per share. It mobilised ₹1,016 crore from anchor investors ahead of the IPO.
Since the IPO was entirely an offer-for-sale (OFS), the proceeds will go to the selling shareholders.
As at 11.19 am, the stock traded at ₹725.15 on the NSE and at ₹724.75 on the BSE.
Published on July 21, 2025
